What one share of Cue Biopharma holds
We are a clinical-stage biopharmaceutical company developing a novel class of injectable therapeutics engineered to selectively engage and modulate disease-specific T cells for the treatment of autoimmune and inflammatory diseases.
Cue Biopharma’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $8.33 |
|---|---|
| Profit | −$36.32 |
| Capex (buildings and equipment) | $0.03 |
| Free cash flow | −$11.10 |
| Cash and investments | $3.33 |
| Book value | $0.44 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2017 | — | −$64.94 | $2.88 | −$36.82 | — | $94.98 |
| 2018 | $1.70 | −$58.08 | $2.76 | −$42.12 | — | $49.24 |
| 2019 | $4.71 | −$49.95 | $0.06 | −$41.98 | — | $61.65 |
| 2020 | $3.30 | −$46.83 | $0.62 | −$34.60 | — | $78.00 |
| 2021 | $14.33 | −$42.35 | $0.88 | −$38.12 | — | $61.01 |
| 2022 | $1.05 | −$44.61 | $0.14 | −$35.33 | — | $41.73 |
| 2023 | $3.60 | −$33.26 | $0.00 | −$26.20 | — | $23.56 |
| 2024 | $4.95 | −$21.66 | $0.04 | −$19.38 | — | $8.49 |
| 2025 | $8.70 | −$8.42 | $0.06 | −$6.92 | — | $8.21 |
Common questions about Cue Biopharma
How much does one share of Cue Biopharma earn?
Over the last 12 months, Cue Biopharma lost $36.32 for each share on $8.33 of sales.
Does Cue Biopharma pay a dividend?
Cue Biopharma didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Cue Biopharma’s book value per share?
Cue Biopharma’s book value is $0.44 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Cue Biopharma have?
Each share of Cue Biopharma has $3.33 of cash and investments, as of June 30, 2026.
What is Cue Biopharma’s free cash flow per share?
−$11.10 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Cue Biopharma bought back shares?
Cue Biopharma’s share count rose about 783% from 2017 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.